2,4-Diamino(ring-U-14C)anisole 2HCl administered i.p. to rats was excreted chiefly via the urine (79 and 85% of the dose in 24 and 48 h, respectively). The isotope in the feces was 2.1 and 8.9% of the dose at 24 and 48 h. The major metabolic pathway was acetylation of the amine group(s), resulting in 4-acetylamino-2-aminoanisole and 2,4-diacetylaminoanisole. Oxidative pathways yielded 2,4-diacetylaminophenol (O-demethylation), 5-hydroxy-2,4-diacetylaminoanisole (ring hydroxylation) and 2-methoxy-5-(glycolamido)acetanilide or its isomer (omega-oxidation). These major metabolites were excreted in the urine as free and glucuronic acid conjugates.
Evaluation: There is inadequate evidence in humans for the carcinogenicity of 2,4-diaminoanisole. There is sufficient evidence in experimental animals for the carcinogenicity of 2,4-diaminoanisole. Overall evaluation: 2,4-Diaminoanisole is possibly carcinogenic to humans (Group 2B). /2,4-Diaminoanisole and its salts/
来源:Hazardous Substances Data Bank (HSDB)
毒理性
副作用
高铁血红蛋白血症 - 血液中高铁血红蛋白含量增加；该化合物被归类为次要的毒性效应。
Methemoglobinemia - The presence of increased methemoglobin in the blood; the compound is classified as secondary toxic effect
来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases
Male Wistar rats were divided into two groups. Rats of group 1 were fed basal powdered diet containing 610 ppm 2,4- diaminoanisole sulfate (DAAS), 46 ppm 4,4'-thiodianiline (TDA) and 200 ppm N,N'-diethylthiourea (DETU) for 52 weeks (DTD treatment). Rats of group 2 were maintained on basal diet throughout the experiment as controls. At 52 weeks all surviving rats were sacrificed and subjected to an autopsy. Thyroid, lungs, stomach, liver, spleen, kidneys, testes and all gross lesions suspected of being a tumor were removed. After DTD treatment, the incidence of thyroid hyperplasia and papillary thyroid carcinoma was 59% (10/17) and 65% (11/17), respectively. Hepatocellular adenoma was induced in 2 of 17 rats (12%). Papillary thyroid carcinoma metastasis was found in the lung of 1 rat. No neoplastic tumors were found in kidney, spleen, stomach and testis tissue. /2,4-diaminoanisole sulfate/
Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if necessary. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mg/kg up to 200 ml of water for dilution if the patent can swallow, has a strong gag reflex, and does not drool. Administer activated charcoal ... . Cover skin burns with dry sterile dressings after decontamination ... . /Organic bases/Amines and related compounds/
Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag-valve-mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's (LR) if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. If patient is unresponsive to these measures, vasopressors may be helpful. Watch for signs of fluid overload ... . Administer 1% solution methylene blue if patient is symptomatic with severe hypoxia, cyanosis, and cardiac compromise not responding to oxygen. ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Organic bases/Amines and related compounds/
The percutaneous absorption of 2,4-diaminoanisole dihydrochloride by hairless rats was approx 2 times higher than that of 2-(2,4-diaminophenoxy)ethanol dihydrochloride because of its high lipid affinity. The penetration of both compounds through the skin was concentration-dependent and studied by (14)C-labelling.
A process for the manufacture of substantially pure 3-amino-4-alkoxy-acylanilides from 2,4-dinitrochlorobenzene
申请人：Toms River Chemical Corporation
公开号：EP0011048B1
公开（公告）日：1982-01-27
REAGENT FOR MEASURING AGGREGATION AND METHOD OF MEASURING AGGREGATION
申请人：Sekisui Medical Co., Ltd.
公开号：EP1970704B1
公开（公告）日：2016-07-13
Reagent for Measuring Agglutination and Method of Measuring Agglutination
申请人：Yamamoto Mitsuaki
公开号：US20100167310A1
公开（公告）日：2010-07-01
[PROBLEMS] To provide a reagent for measuring agglutination by using a reaction accelerator, which causes no spontaneous agglutination of receptor-sensitized carrier particles in the coexistence of these carrier particles, and a measurement method.
[MEANS FOR SOLVING PROBLEMS] A reagent for measuring agglutination by using a specific amine compound, whereby aggregation based on a specific reaction can be accelerated without causing spontaneous agglutination of carrier particles, and measurement method.
METHOD AND KIT FOR QUANTIFYING LIVER-TYPE FATTY ACID BINDING PROTEIN, METHOD AND KIT FOR TESTING FOR KIDNEY DISEASES, AND COMPANION DIAGNOSTIC DRUG
申请人：CMIC HOLDINGS CO., LTD.
公开号：US20220034909A1
公开（公告）日：2022-02-03
Provided are a method and a kit for quantifying L-FABP or oxidized L-FABP in any sample, a method and a kit for testing for kidney diseases on the basis of the quantifying result of L-FABP or oxidized L-FABP in urine of a subject, and a companion diagnostic drug. This method for quantifying liver type fatty acid binding protein includes a step for promoting an antigen-antibody reaction, and quantifying the liver type fatty acid binding protein under a condition in which the measurement sensitivity of oxidized liver type fatty acid binding protein is higher than that of unoxidized liver type fatty acid binding protein.
